Ark Pharma Limited 31/03/2025 iXBRL

Company registration number: 14884728

Ark Pharma Limited

Unaudited filleted financial statements

31 March 2025

Ark Pharma Limited

Contents

Statement of financial position

Notes to the financial statements

Ark Pharma Limited

Statement of financial position

31 March 2025

		31/03/25		31/03/24
	Note	£	£	£	£

Fixed assets
Investments	5	2,900,471		2,896,032
		_______		_______
			2,900,471		2,896,032

Current assets
Cash at bank and in hand		19,278		19,706
		_______		_______
		19,278		19,706
Creditors: amounts falling due
within one year	6	( 1,194,886)		( 1,171,447)
		_______		_______
Net current liabilities			( 1,175,608)		( 1,151,741)
			_______		_______
Total assets less current liabilities			1,724,863		1,744,291

Creditors: amounts falling due
after more than one year	7		( 1,721,390)		( 1,741,230)
			_______		_______
Net assets			3,473		3,061
			_______		_______

Capital and reserves
Called up share capital			200		200
Profit and loss account			3,273		2,861
			_______		_______
Shareholders funds			3,473		3,061
			_______		_______

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 24 December 2025 , and are signed on behalf of the board by:

Mr Rakesh Bagga Mr Kevel Patel

Director Director

Company registration number: 14884728

Ark Pharma Limited

Notes to the financial statements

Year ended 31 March 2025

1. General information

The company is a private company limited by shares, registered in England & Wales. The address of the registered office is Scottish Provident House, 3rd Floor, 76 - 80 College Road, Harrow, Middlesex, HA1 1BQ. The principal activity of the company is that of a holding company.

2. Statement of compliance

These financial statements have been prepared in compliance with the provision of FRS 102, section 1A, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', and Companies Act 2006 (as applicable to companies subject to the small companies regime).

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis.The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

In accordance with their responsibilities as directors, the directors have considered the appropriateness of the going concern basis for the preparation of the financial statements.The directors have reviewed the impact of the macro-economic uncertainties on the company and consider that these are not expected to affect the company. Accordingly, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus, the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Fixed asset investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 3 (2024: 3 ).

5. Investments

	Shares in group undertakings	Total
	£	£
Cost
At 1 April 2024	2,896,032	2,896,032
Additions	4,439	4,439
	_______	_______
At 31 March 2025	2,900,471	2,900,471
	_______	_______
Impairment
At 1 April 2024 and 31 March 2025	-	-
	_______	_______
Carrying amount
At 31 March 2025	2,900,471	2,900,471
	_______	_______
At 31 March 2024	2,896,032	2,896,032
	_______	_______

6. Creditors: amounts falling due within one year

	31/03/25	31/03/24
	£	£
Bank loans and overdrafts (Note 7.)	96,423	207,328
Amounts owed to group undertakings	496,233	71,000
Other creditors	602,230	893,119
	_______	_______
	1,194,886	1,171,447
	_______	_______

Amount owed to group undertakings are unsecured, interest free and repayable on demand.

Other creditors include amounts owed to directors amounting to £601,030 (2024: £886,719) which are unsecured, interest free and are repayable on demand.

7. Creditors: amounts falling due after more than one year

	31/03/25	31/03/24
	£	£
Bank loans and overdrafts	1,721,390	1,741,230
	_______	_______

The bank loans are secured by: A first legal charge from the company over the leasehold land and building of the company and its subsidiary. An unlimited debenture from Ark Pharma Limited . Additionally, all directors have provided a guarantee for a principal amount of £582,000 plus interest and other costs to the bank. An omnibus guarantee and set off agreement among the Bank and the company and its subsidiary together with such other security as the Bank may from time to time hold in respect of the debts and liabilities of any guarantor to the Bank. The loans are repayable by September 2028 and are interest bearing at commercial rate per annum.

8. Controlling party

In the opinion of the directors, there is no single controlling party in the company.

9. Group financial statements

The company is entitled to the exemption under Section 399 of the Companies Act 2006 from the obligation to prepare group financial statements.